Cumberland Pharmaceuticals CPIX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Acetadote | $508.46K+175% | $185.18K-59.6% | $458.76K-8.4% | $501.04K— | |
| Caldolor | $4.66M-6.0% | $4.96M+14.4% | $4.33M-10.2% | $4.83M— | |
| Kristalose | $10.54M-31.2% | $15.32M-4.2% | $15.98M+5.1% | $15.21M— | |
| Other revenue | $4.13M+210% | $1.33M— | —— | —— | |
| Sancuso | $11.91M+32.2% | $9.01M+11.2% | $8.1M-38.7% | $13.21M— | |
| Vibativ | $11.11M+55.1% | $7.16M-18.8% | $8.81M+17.7% | $7.49M-36.0% | |
| Non-current inventories by Product | |||||
| Acetadote | $120.88K+10.8% | $109.13K— | —— | —— | |
| Caldolor | $572K+102% | $283.29K— | —— | —— | |
| Ifetroban | $321.82K— | —— | —— | —— | |
| Kristalose | $9.62M-16.9% | $11.58M— | —— | —— | |
| Sancuso | $1.65M-24.9% | $2.2M— | —— | —— | |
| Vaprisol | $4.69M— | —— | —— | —— | |
| Vibativ | $19.94M-22.7% | $25.8M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Cumberland Pharmaceuticals break its business down?
- Cumberland Pharmaceuticals (CPIX) reports revenue by product across 7 parts — Acetadote, Caldolor, Kristalose, Other revenue and Sancuso. Each is extracted from the segment footnotes and tracked over time.
- Where does Cumberland Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Cumberland Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
